JP2020507761A - 炎症系疾患の生化学的エンドタイプを定義するalx受容体リガンド - Google Patents
炎症系疾患の生化学的エンドタイプを定義するalx受容体リガンド Download PDFInfo
- Publication number
- JP2020507761A JP2020507761A JP2019541434A JP2019541434A JP2020507761A JP 2020507761 A JP2020507761 A JP 2020507761A JP 2019541434 A JP2019541434 A JP 2019541434A JP 2019541434 A JP2019541434 A JP 2019541434A JP 2020507761 A JP2020507761 A JP 2020507761A
- Authority
- JP
- Japan
- Prior art keywords
- lxa
- alx
- fluid
- saa
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/127—Bronchitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/382—Cystic fibrosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本出願は、2017年1月31日に提出された米国仮出願第62/452,533号の優先権を主張し、この出願は参照により以下に完全に記載されているかのように組み込まれる。
本発明は、国立衛生研究所により授与されたHL109172に基づく政府の支援により行われた。政府は本発明において一定の権利を有する。
a.診断方法
別の実施形態では、本発明は、患者の組織、体液または洗浄液を検査し、リポキシンA4(LXA4)、15−epi−LXA4、および血清アミロイドA(SAA)などの特定のALX受容体リガンドのレベルを測定または検査する方法である。好ましい一実施形態では、3つのマーカーすべてを測定するであろう。別の実施形態では、LXA4および15−epi−LXA4またはSAAと共にLXA4を測定する。本発明の好ましいバージョンでは、マーカーを測定し、LXA4とSAAとの比を決定する。
1.National Current Asthma Prevalence (2014).https://www.cdc.gov/asthma/most_recent_data.htm.
2.Levy BD,Noel PJ,Freemer MM,Cloutier MM,Georas SN,Jarjour NN,et al.Future Research Directions in Asthma.An NHLBI Working Group Report.Am J Respir Crit Care Med 2015;192(11):1366−72.
3.Ray A,Raundhal M,Oriss TB,Ray P,and Wenzel SE.Current concepts of severe asthma.The Journal of clinical investigation.2016;126(7):2394−403.
4.Modena BD,Bleecker ER,Busse WW,Erzurum SC,Gaston BM,Jarjour NN,et al.Gene Expression Correlated to Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease.American journal of respiratory and critical care medicine.2016.
5.Moore WC,Meyers DA,Wenzel SE,Teague WG,Li H,Li X,et al.Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.Am J Respir Crit Care Med.2010;181(4):315−23.
6.Wenzel SE.Asthma phenotypes:the evolution from clinical to molecular approaches.Nat Med.2012;18(5):716−25.
7.Fahy JV.Type 2 inflammation in asthma−−present in most,absent in many.Nat Rev Immunol.2015;15(1):57−65.
8.Serhan CN.Pro−resolving lipid mediators are leads for resolution physiology.Nature.2014;510(7503):92−101.
9.Levy BD,and Serhan CN.Resolution of acute inflammation in the lung.Annual review of physiology.2014;76:467−92.
10.Christie PE,Spur BW,and Lee TH.The effects of lipoxin A4 on airway responses in asthmatic subjects.Am Rev Respir Dis.1992;145(6):1281−4.
11.Ono E,Dutile S,Kazani S,Wechsler ME,Yang J,Hammock BD,et al.Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma.American journal of respiratory and critical care medicine.2014;190(8):886−97.
12.Kazani S,Planaguma A,Ono E,Bonini M,Zahid M,Marigowda G,et al.Exhaled breath condensate eicosanoid levels associate with asthma and its severity.J Allergy Clin Immunol.2013;132(3):547−53.
13.Levy BD,Bonnans C,Silverman ES,Palmer LJ,Marigowda G,Israel E,et al.Diminished lipoxin biosynthesis in severe asthma.Am J Respir Crit Care Med.2005;172(7):824−30.
14.Planaguma A,Kazani S,Marigowda G,Haworth O,Mariani TJ,Israel E,et al.Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma.Am J Respir Crit Care Med.2008;178(6):574−82.
15.Vachier I,Bonnans C,Chavis C,Farce M,Godard P,Bousquet J,et al.Severe asthma is associated with a loss of LX4,an endogenous anti−inflammatory compound.The Journal of allergy and clinical immunology.2005;115(1):55−60.
16.Chiang N,Serhan CN,Dahlen SE,Drazen JM,Hay DW,Rovati GE,et al.The lipoxin receptor ALX:potent ligand−specific and stereoselective actions in vivo.Pharmacological reviews.2006;58(3):463−87.
17.Cooray SN,Gobbetti T,Montero−Melendez T,McArthur S,Thompson D,Clark AJ,et al.Ligand−specific conformational change of the G−protein−coupled receptor ALX/FPR2 determines proresolving functional responses.Proc Natl Acad Sci U S A.2013;110(45):18232−7.
18.Bozinovski S,Uddin M,Vlahos R,Thompson M,McQualter JL,Merritt AS,et al.Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease.Proceedings of the National Academy of Sciences of the United States of America.2012;109(3):935−40fff.
19.He R,Sang H,and Ye RD.Serum amyloid A induces IL−8 secretion through a G protein−coupled receptor,FPRL1/LXA4R.Blood.2003;101(4):1572−81.
20.Perretti M,Chiang N,La M,Fierro IM,Marullo S,Getting SJ,et al.Endogenous lipid−and peptide−derived anti−inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.Nature medicine.2002;8(11):1296−302.
21.Morris T,Stables M,Colville−Nash P,Newson J,Bellingan G,de Souza PM,et al.Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways.Proceedings of the National Academy of Sciences of the United States of America.2010;107(19):8842−7.
22.Fiore S,Maddox JF,Perez HD,and Serhan CN.Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.The Journal of experimental medicine.1994;180(1):253−60.
23.Levy BD,De Sanctis GT,Devchand PR,Kim E,Ackerman K,Schmidt BA,et al.Multi−pronged inhibition of airway hyper−responsiveness and inflammation by lipoxin A(4).Nat Med.2002;8(9):1018−23.
24.Barnig C,Cernadas M,Dutile S,Liu X,Perrella MA,Kazani S,et al.Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.Sci Transl Med.2013;5(174):174ra26.
25.Ariel A,Chiang N,Arita M,Petasis NA,and Serhan CN.Aspirin−triggered lipoxin A4 and B4 analogs block extracellular signal−regulated kinase−dependent TNF−alpha secretion from human T cells.J Immunol.2003;170(12):6266−72.
26.Romano M,Maddox JF,and Serhan CN.Activation of human monocytes and the acute monocytic leukemia cell line (THP−1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4:evidence for differential Ca2+mobilization.J Immunol.1996;157(5):2149−54.
27.Aliberti J,Hieny S,Reis e Sousa C,Serhan CN,and Sher A.Lipoxin−mediated inhibition of IL−12 production by DCs:a mechanism for regulation of microbial immunity.Nature immunology.2002;3(1):76−82.
28.Yang D,Chen Q,Le Y,Wang JM,and Oppenheim JJ.Differential regulation of formyl peptide receptor−like 1 expression during the differentiation of monocytes to dendritic cells and macrophages.J Immunol.2001;166(6):4092−8.
29.Maderna P,Cottell DC,Toivonen T,Dufton N,Dalli J,Perretti M,et al.FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin−derived peptide−stimulated phagocytosis.FASEB journal :official publication of the Federation of American Societies for Experimental Biology.2010;24(11):4240−9.
30.Bonnans C,Fukunaga K,Levy MA,and Levy BD.Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury.The American journal of pathology.2006;168(4):1064−72.
31.Chiang N,Fierro IM,Gronert K,and Serhan CN.Activation of lipoxin A(4) receptors by aspirin−triggered lipoxins and select peptides evokes ligand−specific responses in inflammation.The Journal of experimental medicine.2000;191(7):1197−208.
32.Chiang N,Gronert K,Clish CB,O’Brien JA,Freeman MW,and Serhan CN.Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin−triggered lipoxins in reperfusion.The Journal of clinical investigation.1999;104(3):309−16.
33.Bena S,Brancaleone V,Wang JM,Perretti M,and Flower RJ.Annexin A1 interaction with the FPR2/ALX receptor:identification of distinct domains and downstream associated signaling.The Journal of biological chemistry.2012;287(29):24690−7.
34.Chiang N,Dalli J,Colas RA,and Serhan CN.Identification of resolvin D2 receptor mediating resolution of infections and organ protection.The Journal of experimental medicine.2015;212(8):1203−17.
35.Dakin SG,Martinez FO,Yapp C,Wells G,Oppermann U,Dean BJ,et al.Inflammation activation and resolution in human tendon disease.Science translational medicine.2015;7(311):311ra173.
36.Lee TH,Crea AE,Gant V,Spur BW,Marron BE,Nicolaou KC,et al.Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4,D4,and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases.The American review of respiratory disease.1990;141(6):1453−8.
37.Wu SH,Chen XQ,Liu B,Wu HJ,and Dong L.Efficacy and safety of 15(R/S)−methyl−lipoxin A(4) in topical treatment of infantile eczema.Br J Dermatol.2013;168(1):172−8.
38.Haworth O,Cernadas M,Yang R,Serhan CN,and Levy BD.Resolvin E1 regulates interleukin 23,interferon−gamma and lipoxin A4 to promote the resolution of allergic airway inflammation.Nat Immunol.2008;9(8):873−9.
39.Levy BD,Lukacs NW,Berlin AA,Schmidt B,Guilford WJ,Serhan CN,et al.Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism.FASEB journal :official publication of the Federation of American Societies for Experimental Biology.2007;21(14):3877−84.
40.Gronert K,Martinsson−Niskanen T,Ravasi S,Chiang N,and Serhan CN.Selectivity of recombinant human leukotriene D(4),leukotriene B(4),and lipoxin A(4) receptors with aspirin−triggered 15−epi−LXA(4) and regulation of vascular and inflammatory responses.The American journal of pathology.2001;158(1):3−9.
41.Su SB,Gong W,Gao JL,Shen W,Murphy PM,Oppenheim JJ,et al.A seven−transmembrane,G protein−coupled receptor,FPRL1,mediates the chemotactic activity of serum amyloid A for human phagocytic cells.The Journal of experimental medicine.1999;189(2):395−402.
42.El Kebir D,Jozsef L,Khreiss T,Pan W,Petasis NA,Serhan CN,et al.Aspirin−triggered lipoxins override the apoptosis−delaying action of serum amyloid A in human neutrophils:a novel mechanism for resolution of inflammation.J Immunol.2007;179(1):616−22.
43.Buyukozturk S,Gelincik AA,Genc S,Kocak H,Oneriyidogan Y,Erden S,et al.Acute phase reactants in allergic airway disease.The Tohoku journal of experimental medicine.2004;204(3):209−13.
44.Ather JL,Fortner KA,Budd RC,Anathy V,and Poynter ME.Serum amyloid A inhibits dendritic cell apoptosis to induce glucocorticoid resistance in CD4(+) T cells.Cell death & disease.2013;4:e786.
45.Peters MC,McGrath KW,Hawkins GA,Hastie AT,Levy BD,Israel E,et al.Plasma interleukin−6 concentrations,metabolic dysfunction,and asthma severity:a cross−sectional analysis of two cohorts.Lancet Respir Med.2016;4(7):574−84.
46.Hagihara K,Nishikawa T,Sugamata Y,Song J,Isobe T,Taga T,et al.Essential role of STAT3 in cytokine−driven NF−kappaB−mediated serum amyloid A gene expression.Genes to cells :devoted to molecular & cellular mechanisms.2005;10(11):1051−63.
47.Phipatanakul W,Mauger DT,Sorkness RL,Gaffin JM,Holguin F,Woodruff PG,et al.Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma.Am J Respir Crit Care Med.2016.
48.Chung KF,Wenzel SE,Brozek JL,Bush A,Castro M,Sterk PJ,et al.International ERS/ATS guidelines on definition,evaluation and treatment of severe asthma.Eur Respir J.2014;43(2):343−73.
Claims (17)
- (a)体液、組織または洗浄液を収集または調製するステップと、
(b)体液、組織または洗浄液中のALX受容体リガンドまたはALX受容体発現を測定するステップであって、ALX受容体リガンドのレベルが臨床転帰または治療法の選択を予測する、ステップと
を含む、患者における慢性炎症の疾患の重症度を判定する方法。 - ALX受容体リガンドがLXA4、15−epi−LXA4およびSAAで構成される群より選択される、請求項1に記載の方法。
- 測定が比率をもたらす、請求項1に記載の方法。
- 慢性炎症の疾患が、病的肺炎症、関節炎、炎症性腸疾患、アテローム性動脈硬化症および乾癬で構成される群から選択される、請求項1に記載の方法。
- 肺炎症の疾患が嚢胞性線維症である、請求項4に記載の方法。
- 肺炎症の疾患が喘息である、請求項4に記載の方法。
- 肺炎症の疾患が、COPD、気管支拡張症、細気管支炎、間質性肺疾患、移植拒絶、肺炎、肺膿瘍、肺血管疾患、肺塞栓、およびARDSで構成される群から選択される、請求項4に記載の方法。
- 体液または洗浄液が気管支肺胞洗浄液である、請求項4〜6のいずれか一項に記載の方法。
- 体液、組織または洗浄液は、血液、血清、血漿、尿、鼻洗浄液、痰、呼気凝縮液、涙、母乳、精液、胸膜液、心膜液および関節液で構成される群から選択される、請求項1〜3のいずれか一項に記載の方法。
- リポキシンA4および血清アミロイドAのレベルが測定され、比が肺炎症の増加、喘息症状の増加、肺機能の低下および喘息併存症のリスク増加を含む重篤な疾患の臨床転帰を予測する、請求項2に記載の方法。
- 組織、体液または洗浄液中のマクロファージによるALX/FPR2受容体の発現が、肺炎症の増加、喘息症状の増加、肺機能の低下および喘息併存症のリスク増加を含む重篤な疾患の臨床転帰を予測する、請求項1に記載の方法。
- 体液、組織または洗浄液中のALX受容体リガンドまたはALX受容体発現を測定する方法であって、方法が、
(a)患者の組織、体液または洗浄液を取得するステップと、
(b)体液、組織または洗浄液中のALX受容体リガンドまたはALX受容体発現の量を判定するステップと
を含む、方法。 - 体液、組織または洗浄液は気管支肺胞洗浄液である、請求項12に記載の方法。
- 体液、組織または洗浄液が、血液、血清、血漿、尿、鼻洗浄液、痰、呼気凝縮液、涙、母乳、精液、胸膜液、心膜液および関節液で構成される群から選択される、請求項12に記載の方法。
- 測定が、LXA4、15−epi−LXA4、およびSAAのうちの少なくとも1つの測定である、請求項13または14に記載の方法。
- 測定が、LXA4、15−epi−LXA4、およびSAAのうちの少なくとも2つの測定である、請求項13または14に記載の方法。
- 測定がELISAによるものである、請求項12に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762452533P | 2017-01-31 | 2017-01-31 | |
US62/452,533 | 2017-01-31 | ||
PCT/US2018/015287 WO2018144316A1 (en) | 2017-01-31 | 2018-01-25 | Alx receptor ligands define a biochemical endotype for inflammation-based diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020507761A true JP2020507761A (ja) | 2020-03-12 |
Family
ID=63041024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019541434A Pending JP2020507761A (ja) | 2017-01-31 | 2018-01-25 | 炎症系疾患の生化学的エンドタイプを定義するalx受容体リガンド |
Country Status (7)
Country | Link |
---|---|
US (1) | US11519911B2 (ja) |
EP (1) | EP3576843A4 (ja) |
JP (1) | JP2020507761A (ja) |
CN (1) | CN110709138A (ja) |
AU (1) | AU2018216673B2 (ja) |
CA (1) | CA3052271A1 (ja) |
WO (1) | WO2018144316A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021113498A1 (en) * | 2019-12-03 | 2021-06-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Cyclooxygenase-2 inhibition for the treatment of saa-high asthma |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08512023A (ja) * | 1993-06-15 | 1996-12-17 | ブリガム・アンド・ウイメンズ・ホスピタル | リポキシン化合物 |
US20030120037A1 (en) * | 1999-09-22 | 2003-06-26 | Ji Ming Wang | Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA) |
JP2018522535A (ja) * | 2015-05-22 | 2018-08-16 | ラ トローブ ユニヴァーシティLa Trobe University | 乳癌の診断方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2675416A1 (en) | 1999-03-18 | 2000-09-21 | Brigham And Women's Hospital | Lipoxin compounds and their use |
DK1165066T3 (da) | 1999-03-18 | 2006-03-06 | Brigham & Womens Hospital | Anvendelse af lipoxin-forbindelser til inhibering af TNF-alfa-initieret neutrofil respons |
AU2001249329A1 (en) | 2000-03-20 | 2001-10-03 | Brigham And Women's Hospital | Lipoxin analogs and methods for the treatment of periodontal disease |
ES2316553T3 (es) | 2001-03-02 | 2009-04-16 | The Brigham And Women's Hospital | Analogos de lipoxina como nuevos inhibidores de la angiogenesis. |
US20030166716A1 (en) | 2001-11-06 | 2003-09-04 | Serhan Charles N. | Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
EP1911448B1 (en) | 2001-11-06 | 2013-01-02 | The Brigham and Women's Hospital, Inc. | Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
US6831186B2 (en) | 2001-11-06 | 2004-12-14 | Schering Aktiengesellschft | Lipoxin A4 analogs |
CL2007003468A1 (es) | 2006-12-04 | 2008-07-04 | Bayer Schering Pharma Ag | Sal de potasio cristalina de analogos de lipoxina a4; metodode sintesis; composicion farmaceutica; y uso en el tratamiento de trastornos inflamatorios o autoinmunes. |
CA2986097A1 (en) | 2015-05-18 | 2016-11-24 | The University Of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
US20190033322A1 (en) * | 2016-02-03 | 2019-01-31 | The Cleveland Clinic Foundation | Detection and treatment of il-17 and il-13 related conditions |
-
2018
- 2018-01-25 EP EP18747349.1A patent/EP3576843A4/en active Pending
- 2018-01-25 US US16/482,216 patent/US11519911B2/en active Active
- 2018-01-25 AU AU2018216673A patent/AU2018216673B2/en active Active
- 2018-01-25 JP JP2019541434A patent/JP2020507761A/ja active Pending
- 2018-01-25 CN CN201880019779.8A patent/CN110709138A/zh not_active Withdrawn
- 2018-01-25 CA CA3052271A patent/CA3052271A1/en active Pending
- 2018-01-25 WO PCT/US2018/015287 patent/WO2018144316A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08512023A (ja) * | 1993-06-15 | 1996-12-17 | ブリガム・アンド・ウイメンズ・ホスピタル | リポキシン化合物 |
US20030120037A1 (en) * | 1999-09-22 | 2003-06-26 | Ji Ming Wang | Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA) |
JP2018522535A (ja) * | 2015-05-22 | 2018-08-16 | ラ トローブ ユニヴァーシティLa Trobe University | 乳癌の診断方法 |
Non-Patent Citations (10)
Title |
---|
ANNA PLANAGUMA: "Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma", AM J RESPIR CRIT CARE MED, vol. 178, no. 6, JPN6022000914, 15 September 2008 (2008-09-15), pages 574 - 582, XP055531714, ISSN: 0004689623, DOI: 10.1164/rccm.200801-061OC * |
BRUCE D. LEVY: "Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Di", FRONT IMMUNOL, vol. 3, JPN6022000915, 28 December 2012 (2012-12-28), pages 390, ISSN: 0004689622 * |
CHARLES N SERHAN: "n The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution", REVIEW SEMIN IMMUNOL, vol. 27, no. 3, JPN6022000908, 7 April 2015 (2015-04-07), pages 200 - 215, XP055531711, ISSN: 0004689629, DOI: 10.1016/j.smim.2015.03.004 * |
DRISS EL KEBIR: "15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury", AM J RESPIR CRIT CARE MED, vol. 180, no. 4, JPN6022000910, 15 August 2009 (2009-08-15), pages 311 - 319, XP055531696, ISSN: 0004689627, DOI: 10.1164/rccm.200810-1601OC * |
ISABELLE VACHIER: "Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound", COMPARATIVE STUDY J ALLERGY CLIN IMMUNOL, vol. 115, no. 1, JPN6022000912, January 2005 (2005-01-01), pages 55 - 60, ISSN: 0004689625 * |
LOUIS-PHILIPPE BOULET: "Asthma-related comorbidities", REVIEW EXPERT REV RESPIR MED, vol. 5, no. 3, JPN6022000907, June 2011 (2011-06-01), pages 377 - 393, ISSN: 0004689630 * |
N CHIANG: "Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exud", J PHARMACOL EXP THER, vol. 287, no. 2, JPN6022000911, November 1998 (1998-11-01), pages 779 - 790, XP055531687, ISSN: 0004689626 * |
NAN CHIANG: "The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo", REVIEW PHARMACOL REV, vol. 58, no. 3, JPN6022000909, November 2006 (2006-11-01), pages 468 - 487, ISSN: 0004689628 * |
SHAMSAH KAZANI: "Exhaled breath condensate eicosanoid levels associate with asthma and its severity", J ALLERGY CLIN IMMUNOL, vol. 132, no. 3, JPN6022000913, 19 April 2013 (2013-04-19), pages 547 - 553, XP055735520, ISSN: 0004689624, DOI: 10.1016/j.jaci.2013.01.058 * |
STEVEN BOZINOVSKI: "Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic", PROC NATL ACAD SCI USA, vol. 109, no. 3, JPN6022000916, 3 January 2012 (2012-01-03), pages 935 - 940, ISSN: 0004689621 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018216673B2 (en) | 2023-08-10 |
US11519911B2 (en) | 2022-12-06 |
AU2018216673A1 (en) | 2019-08-29 |
CN110709138A (zh) | 2020-01-17 |
EP3576843A1 (en) | 2019-12-11 |
US20190391145A1 (en) | 2019-12-26 |
WO2018144316A1 (en) | 2018-08-09 |
EP3576843A4 (en) | 2020-11-11 |
CA3052271A1 (en) | 2018-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Allergen-induced increases in sputum levels of group 2 innate lymphoid cells in subjects with asthma | |
Di Stefano et al. | STAT4 activation in smokers and patients with chronic obstructive pulmonary disease | |
Freeman et al. | Cytotoxic potential of lung CD8+ T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15 | |
Müller et al. | High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration | |
Esser et al. | Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue | |
Provost et al. | CCL26/eotaxin-3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin-1 and CCL24/eotaxin-2 | |
Blake et al. | C-reactive protein and other inflammatory risk markers in acute coronary syndromes | |
Michel et al. | Healthy subjects express differences in clinical responses to inhaled lipopolysaccharide that are related with inflammation and with atopy | |
Hoppenot et al. | Peripheral blood Th9 cells and eosinophil apoptosis in asthma patients | |
Prasse et al. | CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis | |
Pardo et al. | CCL18/DC-CK-1/PARC up-regulation in hypersensitivity pneumonitis | |
Penninx et al. | Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study | |
Zhao et al. | Th17 immunity in patients with allergic asthma | |
Ricklefs et al. | ALX receptor ligands define a biochemical endotype for severe asthma | |
Dorman et al. | Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation | |
Lunding et al. | Poly (inosinic-cytidylic) acid–triggered exacerbation of experimental asthma depends on IL-17A produced by NK cells | |
Soria-Castro et al. | Severe COVID-19 is marked by dysregulated serum levels of carboxypeptidase A3 and serotonin | |
TR201807733T4 (tr) | Düşük dereceli inflamasyon için tahmin edici işaretçi olarak çözünebilir ürokinaz plazminojen aktivatör reseptörü (suPAR). | |
Meller et al. | Chemokine responses distinguish chemical-induced allergic from irritant skin inflammation: memory T cells make the difference | |
Okonko et al. | Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK–STAT signal transduction | |
Shilovskiy et al. | Modern view of neutrophilic asthma molecular mechanisms and therapy | |
Moran et al. | Recurrent airway obstruction in horses-An allergic inflammation: a review. | |
Asosingh et al. | Allergen-induced, eotaxin-rich, proangiogenic bone marrow progenitors: a blood-borne cellular envoy for lung eosinophilia | |
Pignatti et al. | Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways | |
Halter et al. | T regulatory cells activation and distribution are modified in critically ill patients with acute respiratory distress syndrome: a prospective single-centre observational study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210115 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220422 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |